Colorectal cancer remains one of the most common and lethal cancers worldwide, and its notorious cellular heterogeneity has long frustrated efforts to understand why some tumors progress relentlessly while others respond to treatment. Tumors are not uniform masses of identical cells; they contain diverse populations of cancer cells, immune cells and stromal cells that communicate with one another and collectively shape disease course. Understanding which specific cell types harbor the molecular programs responsible for malignancy is therefore a central question in cancer biology, and answering it requires looking beyond conventional bulk analyses that average signals across thousands of mixed cells.

The research team assembled an extraordinary dataset to tackle this problem. They integrated data from 2,993 colorectal cancer samples spanning four complementary technologies: bulk RNA sequencing from 2,568 samples drawn from two overall survival and recurrence-free survival cohorts; single-cell RNA sequencing capturing 281,961 individual cells from 152 specimens; spatial transcriptomics from six samples, which preserves information about where genes are expressed within intact tissue; and proteomics from 267 samples, which measures the actual proteins produced by tumor cells. This integrated approach allowed the investigators to move from population-level associations down to individual cells and back up to clinically validated signatures, a strategy increasingly seen as the gold standard for dissecting tumor complexity.

Using computational methods to integrate and annotate the single-cell data, the researchers constructed a stage-stratified atlas of colorectal cancer and resolved eleven distinct malignant epithelial subsets within tumors. Among these, one cluster stood out. Designated Epi_4, this subset was enriched in late-stage tumors and carried strong signatures of epithelial-mesenchymal transition, the process by which epithelial cells acquire migratory and invasive properties; hypoxia, reflecting the low-oxygen conditions typical of growing tumors; and inflammatory programs. Critically, patients whose tumors showed high activity in this subset had significantly worse overall survival and recurrence-free survival across the bulk RNA sequencing cohorts.

The defining molecular marker of this aggressive subset proved to be GPRC5A, a gene encoding a G protein-coupled receptor, a class of cell-surface proteins renowned for their roles in cellular signaling and their historical success as drug targets. The researchers designated this population GPRC5A-positive epithelial cells. GPRC5A expression rose steadily from stage I through stage IV disease, tracking with tumor progression, and elevated levels were associated with poor outcomes across multiple independent cohorts. Spatial transcriptomics confirmed that GPRC5A-positive cells occupied specific locations within tumor tissue consistent with the single-cell findings, and proteomic measurements at the protein level corroborated the RNA-based observations, providing a rare degree of concordance across molecular layers.

Correlation alone, however, does not establish function. To test whether GPRC5A actively drives malignant behavior or merely marks it, the team performed CRISPR-based perturbation experiments in colorectal cancer cell lines, altering GPRC5A expression and observing the consequences. Disrupting the gene affected cell proliferation, migration and invasion, the hallmarks of metastatic potential. Immunoblotting revealed corresponding changes in epithelial-mesenchymal transition markers, indicating that GPRC5A influences the molecular machinery that governs cellular plasticity. In mouse xenograft models, manipulating GPRC5A altered tumorigenicity, the capacity of cancer cells to seed and sustain tumors in living tissue. Together, these experiments support the conclusion that GPRC5A is not simply a passive biomarker but a functionally important contributor to malignant phenotypes, at least in the models tested.

The investigators then turned their attention upward along the regulatory hierarchy, asking which molecular master switches control GPRC5A expression. Using SCENIC, a computational framework that infers transcription factor activity from single-cell expression data, combined with analysis of binding motifs in the JASPAR database, they identified FOSL1 as a candidate upstream regulator. FOSL1 belongs to the AP-1 family of transcription factors, well-established players in cancer cell proliferation, invasion and inflammation. Chromatin immunoprecipitation followed by quantitative PCR, a technique that detects whether a specific protein binds to a specific DNA sequence, provided experimental support that FOSL1 physically occupies the GPRC5A promoter region. This finding suggests a concrete regulatory pathway through which malignant epithelial states might be induced and maintained, and it raises the possibility that blocking this axis could suppress the aggressive cell population.

Perhaps the most intriguing dimension of the study concerns the tumor microenvironment, the ecosystem of non-cancerous cells that surrounds and interacts with tumors. Spatial analysis and ligand-receptor mapping, which predicts communication between cell types based on the expression of signaling molecules and their corresponding receptors, revealed a close physical and functional association between GPRC5A-positive epithelial cells and a population of cancer-associated fibroblasts marked by the expression of periostin, designated POSTN-positive fibroblasts. The computational analysis predicted reciprocal signaling between these two cell populations through several ligand-receptor pairs, including COL1A1 interacting with SDC4, COL1A1 and COL1A2 engaging ITGA2 and ITGB1, and PPIA binding BSG. Fibroblasts are known to remodel the extracellular matrix and secrete growth factors that support tumor growth, and this study suggests a potentially reciprocal dialogue in which epithelial cells and fibroblasts reinforce each other’s malignant behaviors. Importantly, patients whose tumors displayed concurrent high signatures of both GPRC5A-positive epithelial cells and POSTN-positive fibroblasts had the worst overall and recurrence-free survival, suggesting that this cellular partnership may be a powerful indicator of aggressive disease.

The translational implications of the work extend to drug response. Using OncoPredict, a computational tool that estimates drug sensitivity from gene expression profiles, the researchers found an association between GPRC5A status and sensitivity to trametinib, an FDA-approved MEK inhibitor used in other cancers. Molecular docking and molecular dynamics simulations produced a computational model of a possible direct interaction between trametinib and the GPRC5A protein, raising the speculative but tantalizing prospect that the drug might act partly through this receptor. The authors are appropriately cautious on this point, emphasizing that the docking model remains experimentally unvalidated and that direct binding studies will be required before any therapeutic conclusion can be drawn. Cell sensitivity assays provided additional exploratory support for the link between GPRC5A and trametinib response, but the researchers stress that this line of investigation is hypothesis-generating rather than definitive.

The study’s conclusions are carefully hedged in ways that reflect both its ambition and its limitations. The authors state that GPRC5A-positive epithelial cells represent a malignancy-associated state in colorectal cancer and that GPRC5A is functionally important for malignant phenotypes in the tested models, conclusions that are well supported by their convergent evidence. However, they explicitly note that the inferred relationships with POSTN-positive fibroblasts and the trametinib findings should be regarded as hypothesis-generating pending functional crosstalk experiments, direct binding validation and therapeutic testing. This level of rigor is notable in a field where single-cell findings are sometimes overinterpreted, and it sets a clear roadmap for follow-up studies: co-culture systems to test epithelial-fibroblast signaling, biophysical assays to confirm or refute trametinib binding to GPRC5A, and ultimately clinical evaluation of GPRC5A as a biomarker for patient stratification.

The work also received approval from institutional ethics committees and was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from all participants and animal procedures reviewed by the appropriate ethics board. Supported by funding from Anhui Provincial and Bengbu Municipal research programs, the study exemplifies how relatively modest clinical research institutions can now leverage large public datasets and advanced molecular platforms to make contributions of genuine translational significance. If subsequent studies validate the central role of the GPRC5A-positive epithelial state and its interaction with the stromal compartment, the findings could eventually inform diagnostic tests that identify high-risk patients and therapeutic strategies aimed at disrupting the epithelial-fibroblast axis or exploiting the drug sensitivity patterns uncovered here. For now, the study stands as a compelling demonstration of how multi-omics integration can transform a heterogeneous tumor mass into a legible map of malignant cell states, communication networks and therapeutic vulnerabilities.

Survival analysis has been a cornerstone of cancer research, underpinning clinical decision-making and therapeutic strategies. Historically, prognostic models relied heavily on aggregated data derived from tumor tissues as a whole, obscuring the heterogeneity inherent in malignant cell populations. scSurvival disrupts this paradigm by dissecting transcriptomic profiles down to single-cell resolution, thereby enabling direct correlation of tumor cell subpopulations with patient survival metrics. This nuanced approach offers a more precise identification of both deleterious and protective cellular components within tumors, fundamentally altering our understanding of tumor biology.

The technological novelty of scSurvival lies in its capacity to integrate advanced artificial intelligence algorithms with high-dimensional single-cell sequencing data. By moving beyond traditional predictive models that average signals across thousands or millions of cells, scSurvival captures intricate biological patterns often lost in bulk analyses. This complexity enables the identification of specific cell states within the tumor microenvironment that either expedite disease progression or contribute to better patient outcomes. Such differentiation has been elusive until now, owing to the sheer cellular diversity and dynamic nature of malignancies.

Co-lead author Tao Ren, Ph.D., emphasizes that scSurvival marks the first direct link between individual tumor cells and patient survival in a single-cell context. This novel analytic technique distinguishes the contributions of distinct cellular subtypes rather than homogenizing tumor cells into a uniform dataset. The approach has profound implications for precision oncology, as it sheds light on disease-driving cells and facilitates tailored interventions targeting these critical populations. The capability to resolve intratumoral heterogeneity at this scale is a monumental stride in cancer biology.

Faming Zhao, Ph.D., another co-lead author and an expert in cancer biology, echoes the transformative potential of this approach. Tumors comprise highly complex ecosystems with varying cellular phenotypes that conventional methods average indiscriminately, thereby blunting the detection of key prognostic signals. By calibrating survival predictions to single-cell data, scSurvival reveals why patients sharing identical histological diagnoses may experience markedly different clinical outcomes. This level of resolution opens avenues for personalized therapy and more accurate risk stratification.

The researchers rigorously validated scSurvival on datasets from melanoma and liver cancer patients, demonstrating superior prognostic accuracy compared to standard survival analysis techniques. Intriguingly, the model illuminated specific immune and tumor cell states intimately linked to survival differences. For instance, certain immune cell populations positively correlated with improved responses to immunotherapy, while others were associated with adverse prognoses. These insights into tumor-immune dynamics present vital clues for enhancing therapeutic efficacy and designing novel immuno-oncology interventions.

Senior author Zheng Xia, Ph.D., a biomedical engineering associate professor at OHSU, highlights that this breakthrough stems from interdisciplinary synergy among computational scientists, cancer biologists, and clinicians. The collective expertise enabled the development of an artificial intelligence framework that adeptly interprets highly complex single-cell genomic data within the context of survival outcomes. This multifaceted collaboration exemplifies the power of integrating diverse scientific domains to solve previously intractable problems in oncology.

The technical sophistication of scSurvival surpasses conventional machine learning approaches by modeling nonlinear relationships and capturing subtle biological phenomena that evade simpler algorithms. By leveraging deep learning architectures and survival analysis statistics simultaneously, the model discerns latent cellular features that influence prognosis. This hybrid computational strategy heralds a new generation of predictive tools poised to transform cancer research, diagnostics, and treatment optimization.

Understanding the heterogeneous cellular makeup of tumors bears critical therapeutic significance. Since tumors consist of multiple cell types exhibiting distinct behaviors—including cancerous cells, stromal cells, and various immune infiltrates—ignoring this complexity can undermine treatment efficacy. scSurvival’s cellular-level prognostication helps identify high-risk patients whose tumors harbor aggressively malignant populations, thereby facilitating more informed clinical decisions and improved patient management through precision medicine.

Though scSurvival is not yet incorporated into routine clinical practice, its open-source availability invites broad adoption and iterative enhancement by the scientific community. The research team has made the software and comprehensive tutorials freely accessible on platforms such as GitHub, Zenodo, and Code Ocean, fostering transparency and accelerating translational applications. This democratized approach to computational oncology underscores the potential for rapid innovation and collaboration on life-saving technologies.

Beyond prognostication, the implications of scSurvival extend into drug development and biomarker discovery. By delineating the cellular drivers of survival disparities, researchers can prioritize molecular targets for novel therapeutics and develop companion diagnostics to monitor treatment responses. Such focused strategies promise to enhance the clinical management of malignancies by tailoring interventions that disrupt key pathological cell populations within tumors.

The funding support for this research reflects the high priority placed on advancing cancer biology and computational methods. The National Institutes of Health, the U.S. Department of Defense, and prominent cancer-focused foundations provided critical resources enabling this interdisciplinary endeavor. The synergy of modern biological technologies and sophisticated computational tools epitomizes the future direction of oncology research and patient care innovation.

OHSU’s scSurvival represents a paradigm shift in oncology research by uniting single-cell genomics and artificial intelligence to decode the cellular determinants of cancer patient survival. This pioneering method not only deepens our biological understanding of tumor heterogeneity and immune interactions but also paves the way for more precise, patient-specific prognostic models. As the field continues to evolve, scSurvival offers a vivid example of how technology-driven insights can translate into enhanced clinical outcomes and personalized medicine.

Subject of Research: Cells

Article Title: (Not provided in the source text)

News Publication Date: 21-Apr-2026

Web References:

• https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0965
• GitHub: scSurvival
• Zenodo: scSurvival
• Code Ocean: scSurvival

Image Credits: OHSU/Christine Torres Hicks

Keywords: Cancer cells, Morbidity, Artificial intelligence

At the heart of this research lies the concept of cellular plasticity, the ability of cells to transition between different functional states in response to environmental cues and internal signals. Hepatocytes are not frozen in a single identity; rather, they exhibit a spectrum of phenotypic states that enable adaptation, repair, and resilience following injury. By employing advanced single-cell sequencing technologies and sophisticated lineage tracing models, the researchers meticulously charted the trajectories of hepatocyte states under conditions mimicking chronic liver injury and tumorigenesis.

The liver’s capacity to regenerate is well known, but until now, the molecular underpinnings linking hepatocyte plasticity with cancer suppression had remained elusive. The team demonstrated that during early neoplastic processes, a distinct subset of hepatocytes undergoes a controlled shift into a plastic state characterized by transient downregulation of mature liver functions and upregulation of progenitor-like gene programs. Intriguingly, these plastic states act as a “functional brake” on tumor progression, preventing the unchecked expansion of malignant clones.

Mechanistically, the study highlights several key signaling pathways that orchestrate this reversible plasticity. Among them, the Hippo-YAP pathway emerges as a master regulator, modulating cellular proliferation and differentiation balancing. Activation of YAP signaling prompted hepatocytes to enter a plastic state; however, intricate feedback loops ensured that this state remained balanced and transient rather than irreversible. Disruption of this regulatory circuit tipped the balance towards malignant transformation, underscoring the importance of precise control in hepatocyte plasticity.

In addition, epigenetic modulators were found to prime hepatocytes for plasticity by remodeling chromatin accessibility. Histone modifications and DNA methylation patterns dynamically shifted during plastic transitions, enabling rapid transcriptional rewiring. These epigenomic landscapes provided a molecular scaffold that facilitated hepatocytes’ quick responses to liver damage and early oncogenic insults. Such plasticity may represent an evolutionary strategy to ensure robust liver function and prevent cancer by transiently suppressing oncogenic drivers.

The investigators also explored how the liver microenvironment influences hepatocyte plasticity. Nonparenchymal cells, including hepatic stellate cells and Kupffer macrophages, emit contextual cytokines and growth factors that fine-tune hepatocyte states. During chronic inflammation or fibrosis, hepatocyte plasticity can be either enhanced or impaired depending on the nature and duration of microenvironmental signals. For example, TGF-β signaling had a dual role, sometimes fostering protective plasticity but under chronic exposure potentially promoting fibrosis and carcinogenesis.

Importantly, the authors employed various murine liver cancer models to demonstrate that enforcing hepatocyte plasticity in vivo limited tumor initiation and growth. Genetic activation of plasticity-inducing pathways reduced tumor burden and improved survival. Conversely, loss-of-function models with impaired plasticity showed accelerated tumorigenesis. These causative experiments solidify plastic hepatocyte states as a natural suppressor mechanism of liver cancer, opening new avenues for therapeutic strategies that reinforce beneficial plasticity to prevent or treat liver malignancies.

The translational implications of this discovery are profound. Current therapeutic approaches for liver cancer, including targeted therapies and immunotherapies, have limited efficacy and substantial side effects. The concept of manipulating hepatocyte plasticity represents an innovative paradigm shift. Therapies could be designed to promote protective plastic states or restore plasticity in damaged livers, potentially halting early tumor development before the disease becomes clinically evident. This precision medicine approach could revolutionize liver cancer prevention and transform patient outcomes.

Furthermore, the plastic hepatocyte states uncovered in this study may serve as biomarkers for assessing liver cancer risk. Characterization of circulating or tissue-resident hepatocyte populations exhibiting plastic phenotypes could enable early detection of cancer-prone microenvironments. Combining such biomarkers with imaging and molecular diagnostics could lead to enhanced surveillance and timely intervention, particularly in high-risk patients with chronic liver disease or viral hepatitis.

The study also invites broader reflections on the fundamental biology of epithelial plasticity in organ homeostasis and cancer. The liver, with its exceptional regenerative capacity, exemplifies how controlled cellular plasticity is harnessed to balance repair and tumor suppression. This raises the possibility that similar plasticity-based mechanisms operate in other epithelial tissues prone to cancer, such as the lung, pancreas, and gastrointestinal tract. Cross-disciplinary research could uncover common principles and identify universal targets for cancer prevention.

Despite these exciting insights, the authors acknowledge several questions that remain unanswered. The exact molecular triggers that initiate plastic transitions in hepatocytes during oncogenic stress are not fully delineated. The long-term consequences of sustaining plastic states, particularly in humans with complex liver pathologies, require further study. Additionally, translating these findings into safe and effective therapies will demand careful dissection of signaling networks to avoid unintended promotion of fibrosis or tumor progression.

Nevertheless, the demonstration that plastic hepatocyte states act as intrinsic barriers to liver cancer development is a landmark advance. By illuminating how the liver’s own cellular dynamics thwart tumor initiation, this research paves the way for a new frontier in oncology that leverages physiological plasticity for disease control. Future studies building on this foundation promise to unravel deeper complexities of liver biology and ignite innovations in cancer prevention and regenerative medicine.

In conclusion, the findings from Strathearn, Hayata, Illendula, and colleagues represent a paradigm shift in our understanding of liver cancer biology. Unraveling how plasticity in hepatocyte states fortifies the liver against malignancy not only enriches fundamental science but also inspires transformative therapeutic strategies. As liver cancer incidence continues to rise globally, harnessing the protective power of hepatocyte plasticity offers hope for more effective, less toxic interventions. The road from bench to bedside may be challenging, but this study charts an inspiring path forward that could dramatically alter the landscape of liver cancer treatment and prevention.

Their research underscores the importance of viewing cancer not merely as a disease of genetic mutations but as a complex interplay of cellular states and tissue environments. The plasticity of hepatocytes exemplifies how the liver exploits flexibility and adaptability at a cellular level to enforce tumor-suppressive programs. This holistic perspective is crucial for the next generation of cancer research and therapeutic design, where the goal is to restore and enhance the body’s natural defenses rather than solely target tumor cells directly.

Moreover, this work highlights the remarkable power of single-cell and epigenomic technologies to tease apart cellular heterogeneity within complex tissues. The ability to resolve transient, plastic cellular states that were previously invisible is revolutionizing our understanding of tissue homeostasis and disease. These insights provide an unprecedented window into the earliest events of cancer development, which are critical for devising preemptive strategies.

As the global burden of liver cancer escalates — driven by factors such as viral hepatitis, alcohol use, and metabolic syndrome — novel approaches informed by fundamental biology are urgently needed. Harnessing hepatocyte plasticity could become a cornerstone of future liver cancer prevention programs, especially in populations at high risk. This research not only elucidates a fascinating aspect of liver physiology but also offers a new beacon of hope in the fight against one of the deadliest human cancers.

In the coming years, further exploration of the molecular circuits governing hepatocyte plasticity and their interactions with the immune system, microbiome, and systemic metabolism will be essential. A deeper understanding of these complex layers will enable the development of refined therapies that precisely modulate plasticity for optimal cancer suppression with minimal adverse effects. The intersection of regenerative biology, epigenetics, and oncology exemplified in this study promises to transform liver cancer prevention from a daunting challenge into a manageable clinical reality.

Subject of Research:
The intrinsic plasticity of hepatocyte states as a natural barrier against liver cancer development, focusing on cellular, molecular, and epigenetic mechanisms that enable transient phenotypic transitions to suppress tumor initiation and progression.

Article Title:
Plastic hepatocyte states limit liver cancer development

Article References:
Strathearn, L.S., Hayata, Y., Illendula, A. et al. Plastic hepatocyte states limit liver cancer development. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66568-0

Image Credits: AI Generated

Unlike typical bladder cancers that exhibit predictable histological features and respond to established therapeutic regimens, HV bladder cancers display a bewildering array of morphological variations under microscopic examination. These tumors often evade standard chemotherapy and immunotherapy, leaving radical surgery as the primary, albeit insufficient, curative option. The recurrence rate remains alarmingly high, underscoring an urgent need for innovative, targeted treatment modalities.

The UCSF team employed an advanced single-cell sequencing platform developed within their lab, allowing unprecedented resolution insight into the genetic and molecular underpinnings of these diverse tumors. By analyzing gene expression profiles at the individual tumor cell level, they discerned a unique molecular signature shared across HV subtypes. Most strikingly, the presence of the carbohydrate antigen 125 (CA125), a marker conventionally associated with ovarian malignancies, was identified on the surface of HV tumor cells but conspicuously absent in conventional bladder cancers.

This unexpected discovery of CA125 expression in bladder tumors challenged existing paradigms and opened new therapeutic avenues. Guided by this insight, the researchers further characterized HV tumors and uncovered the consistent expression of TM4SF1, a transmembrane protein implicated in tumor progression and metastasis. This protein emerged as a promising target for immunotherapeutic intervention, spurring the development of chimeric antigen receptor T-cell (CAR-T) therapy engineered specifically to seek and eradicate TM4SF1-expressing tumor cells.

In preclinical models, CAR-T cells designed to recognize TM4SF1 demonstrated remarkable efficacy, homing to bladder tumors in mice and eliminating malignant cells with precision. These results mark a pivotal advancement, offering compelling evidence that immunotherapy tailored to HV bladder cancer’s unique molecular landscape might overcome the traditional barriers posed by tumor heterogeneity.

Crucial to this breakthrough was the integration of cutting-edge genomic technologies with translational oncology expertise. By leveraging single-cell RNA sequencing, the UCSF researchers deciphered the complex tumor microenvironment and pinpointed molecular vulnerabilities previously concealed within the diverse cellular tapestry of HV bladder cancers. This technological synergy accelerated the translation from tumor characterization to therapeutic innovation within a remarkably condensed timeframe.

As Dr. Sima Porten, co-senior author and associate professor of urology at UCSF, delineated, the conventional clinical approach to HV bladder tumors has been constrained by their variability and the consequent challenges in standardizing treatment strategies. The UCSF team’s findings herald a new epoch where individualized molecular markers like CA125 and TM4SF1 can serve as linchpins for precision medicine, enabling personalized immunotherapeutic interventions.

The implications for patient care are profound. Patients battling HV bladder cancer typically face a grim prognosis due to the paucity of effective systemic therapies. The potential to harness CAR-T cell therapy against TM4SF1-expressing tumors delivers hope for durable responses, possibly transforming an often-fatal diagnosis into a manageable condition. Moreover, the ability to stratify patients based on tumor molecular profiles promises to refine clinical trial designs, fostering inclusive studies that encompass this previously neglected patient cohort.

One of the study’s notable aspects is the multidisciplinary collaboration spanning urology, oncology, genomics, and immunotherapy. The amalgamation of expertise catalyzed the comprehensive analysis of tumor biology and therapeutic engineering, exemplified by the contributions of leading scientists such as Dr. Franklin Huang, who emphasized the translational impact of their single-cell sequencing platform in fast-tracking the identification of actionable targets.

Funding from esteemed entities including the National Institutes of Health (NIH), the Chan-Zuckerberg Biohub, and dedicated urology foundations was instrumental in sustaining this multifaceted research endeavor. Such support underscores the vital importance of fostering innovative cancer research infrastructure capable of bridging fundamental science and clinical application.

While the preclinical success of TM4SF1-targeted CAR-T therapy is promising, the path toward clinical implementation warrants meticulous evaluation. Future studies will need to address therapeutic safety, efficacy in human subjects, potential off-target effects, and the durability of anti-tumor responses. Nonetheless, this groundwork lays a robust foundation for advancing clinical trials tailored to HV bladder cancer patients.

Furthermore, this research ignites a broader discourse on the necessity of integrating high-resolution molecular profiling technologies in oncology. The heterogeneous nature of many cancers demands approaches that begin with understanding the tumor’s cellular heterogeneity at the single-cell level, which can uncover concealed therapeutic targets and resistance mechanisms.

In summation, the UCSF discovery epitomizes how precision medicine, empowered by sophisticated genomic tools and immunotherapy innovation, can redefine treatment paradigms for challenging cancers. The identification of CA125 and TM4SF1 as biomarkers and immunotherapeutic targets in HV bladder tumors inaugurates a hopeful chapter for patients with limited options and inspires a strategic recalibration of future bladder cancer clinical research.

Subject of Research: Histologic variant bladder cancer and targeted immunotherapy development
Article Title: Unavailable
News Publication Date: June 17 (Year not specified)
Web References: Article published in Nature Communications
References: Funded by Chan-Zuckerberg Biohub, UCSF Department of Medicine, NIH (TL1DK139565, U2CDK133488), Urology Care Foundation, California Urology Foundation
Keywords: Cancer, Chimeric antigen receptor therapy, Tumor tissue, Ovarian cancer, Urology, Proteins